DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
AGN-2979 is an investigational drug.
There have been 47 clinical trials for AGN-2979. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2014.
The most common disease conditions in clinical trials are Erythema, Dry Eye Syndromes, and Macular Degeneration. The leading clinical trial sponsors are Allergan, Editas Medicine, Inc., and Naurex, Inc, an affiliate of Allergan plc.
There are five US patents protecting this investigational drug and sixty-four international patents.
Recent Clinical Trials for AGN-2979
|A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease||Allergan||Phase 1/Phase 2|
|AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines||Allergan||Phase 2|
|Single Ascending Dose Study in Participants With LCA10||Editas Medicine, Inc.||Phase 1/Phase 2|
Top disease conditions for AGN-2979
Top clinical trial sponsors for AGN-2979
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AGN-2979||See Pricing||Process for the preparation of 3-aryl-3-aminoalkyl-2,6-dioxohexahydropyridines||G. D. Searle & Co. (Chicago, IL)||See Pricing|
|AGN-2979||See Pricing||Memory-enhancing compositions containing dioxopiperidine derivatives||National Research Development Corporation (London, GB2)||See Pricing|
|AGN-2979||See Pricing||Process for the preparation of diethyl 2-]2-cyano-5-(dimethylamino)-2-(3-methoxyphenyl)-1,1-dimethylpentyl]prop andioate||G. D. Searle & Co. (Chicago, IL)||See Pricing|
|AGN-2979||See Pricing||Piperidin-2,6-dione bisulphate salts and their use for the treatment of stress related affective disorders||Prestwick Pharmaceuticals, Inc. (Washington, DC)||See Pricing|
|AGN-2979||See Pricing||Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders||Prestwick Pharmaceuticals, Inc. (Washington, DC)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AGN-2979||European Patent Office||0448972||2010-02-27||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|